Fifteen-Year Study Reveals How Lipoprotein(a) Levels Shift Over a Lifetime

Lipoprotein(a), the enigmatic cholesterol-carrying particle that has long been considered a fixed genetic fingerprint written at birth, may be less immutable than cardiology textbooks have suggested. A sweeping new analysis of more than 17,000 Taiwanese adults tracked over as long as fifteen years has found that while the vast majority of people keep remarkably steady concentrations of this heart-disease-linked particle, a small but identifiable subset experiences meaningful rises over time. The findings, published in BMC Endocrine Disorders, offer one of the most detailed long-term portraits yet of how lipoprotein(a) behaves in a real-world population, and they carry practical implications for who should have the biomarker rechecked and when.

Lipoprotein(a), abbreviated Lp(a) and often pronounced simply as L-P-little-a, is a low-density lipoprotein particle to which an unusual protein called apolipoprotein(a) is covalently attached. Its concentration in blood is overwhelmingly dictated by the LPA gene, whose size polymorphisms vary dramatically across ethnic groups, and it has emerged over the past decade as one of the most powerful independent genetic risk factors for atherosclerotic cardiovascular disease, aortic valve stenosis and, in some studies, heart failure. Unlike LDL cholesterol, which responds robustly to diet, exercise and most lipid-lowering drugs, Lp(a) has historically resisted every lifestyle intervention thrown at it, fuelling the long-standing assumption that a single lifetime measurement is sufficient for risk stratification.

That assumption is precisely what the new study set out to test. A team of cardiologists and data scientists led by Ming-Lung Tsai of New Taipei Municipal TuCheng Hospital and Dong-Yi Chen of Linkou Chang Gung Memorial Hospital mined the Chang Gung Research Database, one of Taiwan’s largest multi-hospital electronic health record systems, for adults who had at least two Lp(a) measurements taken at least one year apart between January 2004 and December 2019. The retrospective cohort design allowed the researchers to observe how the biomarker drifted, or failed to drift, across a mean follow-up of 5.2 years, with some individuals contributing data across nearly the entire fifteen-year window.

The headline result is one of striking stability. Among the 17,363 participants, who had a mean age of 42.1 years and were 73.3 percent male, the median Lp(a) concentration actually declined slightly over follow-up, falling from 9.3 milligrams per deciliter at baseline to 7.4 milligrams per deciliter at the final measurement. Only 479 participants, a mere 2.8 percent of the cohort, showed an increase of 10 milligrams per deciliter or more, the threshold the investigators pre-specified as a clinically meaningful elevation. For the overwhelming majority, the genetic determinism model of Lp(a) held firm: what was measured in the first blood draw was, within analytical noise, what was measured years later.

But the small minority who did cross the 10-milligram threshold was not random, and this is where the study earns its clinical relevance. Using multivariable logistic regression, the team identified five independent predictors of a substantial Lp(a) rise: a higher baseline Lp(a) concentration, initiation of statin therapy between measurements, a diagnosis of diabetes mellitus, female sex, and higher triglyceride levels. Each of these factors points to a different biological thread, and together they sketch a picture of Lp(a) as a biomarker that, while genetically anchored, can be nudged by metabolic state, medication and perhaps hormonal influences.

The statin finding is likely to draw the most attention, and the most debate. Statins are the workhorse of cardiovascular prevention, yet their relationship with Lp(a) has been contentious for years, with some trials reporting modest increases in the particle among treated patients. The new cohort cannot disentangle whether statin-associated Lp(a) elevation reflects a direct pharmacological effect, a marker of worsening underlying atherosclerosis that prompted statin prescription, or some combination of both, and the authors are careful not to overinterpret the association. What it does suggest is that clinicians who start a patient on a statin and later observe a rising Lp(a) should not automatically assume the measurement is erroneous or that the drug is to blame without considering the broader clinical context.

The diabetes and triglyceride associations are equally intriguing from a mechanistic standpoint. Diabetes is known to influence several apolipoprotein-containing particles, and insulin resistance reshapes hepatic lipid handling in ways that could plausibly alter the assembly or clearance of Lp(a), which is produced almost exclusively by the liver. Higher triglycerides, a hallmark of metabolic syndrome, may similarly mark a hepatic environment in which Lp(a) production or catabolism shifts. The female sex signal, meanwhile, echoes prior observations that Lp(a) concentrations can rise after menopause, hinting at estrogen-related regulation, although the relatively young cohort, with a mean age of just over 42, means the study captured only the early edge of that transition.

For a field racing toward Lp(a)-lowering therapies, these longitudinal data arrive at a propitious moment. RNA-targeted drugs such as pelacarsen, olpasiran and lepodisiran are in late-stage trials and promise, for the first time, to suppress Lp(a) by 80 percent or more. Trial designers and clinicians alike have assumed that a single baseline measurement suffices to identify candidates and to judge treatment response. The new study broadly supports that assumption, since 97 percent of participants remained below the meaningful-change threshold, but it also flags the minority in whom a second measurement could change the risk calculus. The authors conclude that repeat Lp(a) testing may be warranted in selected high-risk individuals, particularly those with elevated baseline values, new diabetes, or newly initiated statin therapy, to sharpen cardiovascular risk stratification.

The study also fills an important geographic gap. Most longitudinal Lp(a) data come from European and North American cohorts, where median concentrations and LPA isoform distributions differ substantially from those in East Asian populations. The Taiwanese cohort’s median baseline value of 9.3 milligrams per deciliter sits well below the roughly 30 to 50 milligrams per deciliter often reported in populations of European descent, a disparity rooted in the frequency of small apolipoprotein(a) isoforms. Demonstrating that Lp(a) stability holds in an Asian population strengthens the case that lifetime genetic determination of this biomarker is a universal feature of human biology, not an artifact of any one ancestry.

Caveats remain, as they do with any retrospective database study. The cohort was predominantly male and middle-aged, the assay methodology was consistent within the health system but may not translate directly to other platforms, and unmeasured factors such as kidney function, thyroid status and inflammatory disease, all of which are known to modulate Lp(a), could not be fully adjusted. The work was funded by Novartis Pharmaceuticals, though the funder had no role in data acquisition, analysis or interpretation, and the authors declare no competing interests. Even with these limitations, the message is clear and reassuring in equal measure: for most people, one well-timed Lp(a) measurement tells you nearly everything you need to know, but for a definable minority, the story written in their genes can still acquire new chapters, and a repeat blood test may be the only way to read them.

Subject of Research: Long-term variability and clinical determinants of lipoprotein(a) concentrations

Article Title: Longitudinal patterns and determinants of lipoprotein(a) variability: a 15-year multi-center study

Article References: Tsai, M.-L., Chen, C.-C., Hsieh, M.-J., Chang, C.-Y., Chen, S.-W., Chen, T.-H., Chu, P.-H., Hsieh, I.-C., Hung, K.-C., Wen, M.-S., & Chen, D.-Y. (2026). Longitudinal patterns and determinants of lipoprotein(a) variability: a 15-year multi-center study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02631-1

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02631-1

Keywords: lipoprotein(a), cardiovascular risk, statins, diabetes mellitus, triglycerides, biomarkers, risk stratification, longitudinal cohort study, dyslipidemia, Taiwan, LDL cholesterol, genetic risk factors